Rodland Karin D, Piehowski Paul, Smith Richard D
From the Pacific Northwest National Laboratory, Richland, WA.
Cancer J. 2018 May/Jun;24(3):121-125. doi: 10.1097/PPO.0000000000000315.
Breaking down the silos between disciplines to accelerate the pace of cancer research is a key paradigm for the Cancer Moonshot. Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids-DNA, RNA, and their modifications-and a focus on proteins and protein function. Proteogenomics represents a fusion of those two approaches, leveraging the strengths of each to provide a more integrated vision of the flow of information from DNA to RNA to protein and eventually function at the molecular level. Proteogenomic studies have been incorporated into multiple activities associated with the Cancer Moonshot, demonstrating substantial added value. Innovative study designs integrating genomic, transcriptomic, and proteomic data, particularly those using clinically relevant samples and involving clinical trials, are poised to provide new insights regarding cancer risk, progression, and response to therapy.
打破学科之间的壁垒以加快癌症研究的步伐是“癌症登月计划”的一个关键范式。癌症生物学的分子分析往往在专注于核酸(DNA、RNA及其修饰)和专注于蛋白质及蛋白质功能之间划分界限。蛋白质基因组学代表了这两种方法的融合,利用每种方法的优势,在分子水平上提供从DNA到RNA再到蛋白质并最终到功能的信息流的更综合视角。蛋白质基因组学研究已被纳入与“癌症登月计划”相关的多项活动中,显示出巨大的附加价值。整合基因组、转录组和蛋白质组数据的创新研究设计,尤其是那些使用临床相关样本并涉及临床试验的设计,有望提供有关癌症风险、进展和治疗反应的新见解。